Forte Biosciences initiated with a Buy at Guggenheim on FB102 potential

As previously reported, Guggenheim initiated coverage of Forte Biosciences (FBRX) with a Buy rating and $75 price target citing a positive view of CD122-blockade as a therapeutic opportunity across a number of severe autoimmune diseases. If approved, the firm estimates about $2.6B risk-unadjusted global peak sales for FB102 across the three autoimmune diseases of celiac disease, vitiligo, and alopecia areata, says the analyst, who expects shares to outperform given three clinical potential catalysts expected in 2026.